首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1169176

皮肌炎治療市場：按藥物類型、給藥途徑、分銷渠道、地區 - 規模、份額、展望、機會分析，2022-2030 年

Dermatomyositis Drug Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年11月08日 | 出版商:

Coherent Market Insights | 英文 166 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

皮肌炎 (DM) 是一種罕見的炎症性肌肉疾病，不僅會影響肌肉，還會影響皮膚。皮肌炎影響所有種族、性別和年齡的人。它在兒童時期對男性和女性的影響相同，但在成年女性中更為常見。 DM 的確切原因尚不清楚，但據信是由遺傳易感個體的外部因素（例如，惡性腫瘤、藥物、傳染源類型）引發的免疫介導過程引起的。皮肌炎可能與其他結締組織病並存，如係統性紅斑狼瘡、類風濕性關節炎、硬皮病、乾燥綜合徵和混合性結締組織病。

市場動態

全球皮肌炎治療市場的主要參與者正專注於採用產品批准等增長戰略，這些戰略有望在預測期內推動市場增長。例如，2018 年 7 月，專注於開發和商業化治療罕見、慢性和嚴重炎症和纖維化疾病的新型療法的 3 期臨床階段製藥公司 Corbus Pharmaceuticals Holdings 宣布，美國食品和藥物管理局已批准孤兒藥指定其新型合成口服內源性大麻素模擬物 lenabasum，用於治療皮肌炎。此外，主要參與者增加治療皮肌炎的研發活動預計將在預測期內推動市場增長。例如，2019年10月21日，生物製藥公司CSL Behring啟動了評估IgPro20（皮下免疫球蛋白，Hizentra）在成人皮肌炎（DM）中的療效、安全性和藥代動力學的3期研究，並開始了試驗。該試驗計劃於 2024 年 2 月結束。

研究的主要特點

本報告對全球皮肌炎藥物市場進行了深入分析，包括以 2021 年為基準年的預測期（2022-2030 年）的市場規模（百萬美元）和復合年增長率 (CAGR%)。 ) 提供。
解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
它還提供了有關市場驅動因素和製約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略的重要見解。
根據以下參數對全球皮肌炎治療市場的主要參與者進行了介紹 - 公司概況、產品組合、主要亮點、財務業績和戰略。
本研究涵蓋的主要公司包括輝瑞公司、Teva Pharmaceuticals USA, Inc.、Hikma Pharmaceuticals PLC、Asahi Kasei Corporation.、Octapharma USA、Healthcare Pharmaceuticals Limited.、Zydus Cadila、Alkem Laboratories Ltd、Apotex Inc.、禮來公司和 F. Hoffman-La Roche Ltd
這份報告中的見解將使企業營銷人員和高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
《全球皮肌炎藥物市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以通過用於分析全球皮肌炎藥物市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

報告內容
- 市場定義和範圍
執行摘要
- 市場概況：按藥物類型
- 按給藥途徑劃分的市場概況
- 市場概況：按分銷渠道
- 市場概況：按地區
連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

市場動態
- 司機
- 約束因素
- 商機
影響分析
監管場景
市場趨勢
主要發展狀況
流行病學
害蟲分析
合作研究和收購
搬運工分析
管道分析

第 4 章全球皮肌炎治療市場 - 冠狀病毒 (COVID-19) 大流行的影響

對經濟的影響
對供需的影響
COVID-19 影響評估

第 5 章按藥物類型分列的皮肌炎藥物全球市場，2017-2030

腎上腺皮質類固醇
免疫抑製劑
其他

第 6 章。全球皮肌炎治療市場：按給藥途徑，2017-2030

口服劑
局部管理
其他

第 7 章。全球皮肌炎治療藥物市場：按分銷渠道，2017-2030

醫院藥房
零售藥房
在線藥店

第 8 章。全球皮肌炎治療市場：按地區劃分，2017-2030

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
法國
意大利
西班牙
俄羅斯
其他歐洲
亞太地區
中國
印度
日本
澳大利亞
韓國
東盟
其他亞太地區
中東
海灣合作委員會
以色列
其他中東地區
非洲
北非
中非
南非

第9章競爭格局

熱圖分析
市場份額分析
- Pfizer Inc.
- Teva Pharmaceuticals USA, Inc.
- Hikma Pharmaceuticals PLC
- Asahi Kasei Corporation.
- Octapharma USA
- Healthcare Pharmaceuticals Limited.
- Zydus Cadila
- Alkem Laboratories Ltd
- Apotex Inc
- Eli Lilly and Co
- Hoffman-La Roche Ltd

第 10 章

調查方法介紹
關於出版商

簡介目錄

Product Code: CMI5333

Dermatomyositis (DM) is a rare inflammatory muscle disease that affects both the muscles as well as the skin. Dermatomyositis can strike people of all races, genders, and ages. Although, both males and females are affected equally in childhood, it is more common in females in adults. The exact cause of DM is unknown but it is believed to result from an immune-mediated process triggered by outside factors (e.g. malignancy, drugs, and infectious Drug Types) in genetically predisposed individuals. Dermatomyositis can occur with other connective tissue disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, and mixed connective tissue disease.

Market Dynamics

Key players operating in the global dermatomyositis drug market are focusing on adoption of growth strategies such as product approvals which is expected to drive the market growth during the forecast period. For instance, in July 2018, Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Moreover, increasing research and development activities by key players for the treatment of dermatomyositis which is expected to drive the market growth over the forecast period. For instance, on October 21, 2019, CSL Behring,a biopharmaceutical company initiated phase 3 Study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in adults with dermatomyositis (DM). The study is estimated to be completed in February 2024.

Key features of the study:

This report provides an in-depth analysis of the global dermatomyositis drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dermatomyositis drug market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, Asahi Kasei Corporation., Octapharma USA, Healthcare Pharmaceuticals Limited., Zydus Cadila, Alkem Laboratories Ltd, Apotex Inc, Eli Lilly and Co, and F.Hoffman-La Roche Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dermatomyositis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis drug market

Detailed Segmentation:

Global Dermatomyositis Drug Market, By Drug Type:
- Corticosteroids
- Immunosuppressive Agents
- Others
Global Dermatomyositis Drug Market, By Route of Administration:
- Oral
- Topical
- Others
Global Dermatomyositis Drug Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Dermatomyositis Drug Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Pfizer Inc *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceuticals USA, Inc.
- Hikma Pharmaceuticals PLC
- Asahi Kasei Corporation
- Octapharma USA
- Healthcare Pharmaceuticals Limited
- Zydus Cadila
- Alkem Laboratories Ltd
- Apotex Inc
- Eli Lilly and Co
- F.Hoffman-La Roche Ltd

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Regulatory Scenario
Market Trends
Key Developments
Epidemiology
PEST Analysis
Collaboration and Acquisition
Porters Analysis
Pipeline Analysis

4. Global Dermatomyositis Drug Market - Impact of Coronavirus (COVID-19) Pandemic

Economic Impact
Impact on Demand and Supply
COVID-19 Impact Assessments

5. Global Dermatomyositis Drug Market, By Drug Type, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Immunosuppressive Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Dermatomyositis Drug Market, By Route of Administration, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

7. Global Dermatomyositis Drug Market, By Distribution Channel, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

8. Global Dermatomyositis Drug Market, By Region, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
U.K.
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
North Africa
Central Africa
South Africa